サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1592587

アジア太平洋のてんかん市場の2030年までの予測 - 地域別分析：タイプ別、投与経路別、治療タイプ別、年齢層別、流通チャネル別

Asia Pacific Epilepsy Market Forecast to 2030 - Regional Analysis - by Type, Route of Administration, Treatment Type, Age Group, and Distribution Channel

出版日
ページ情報
英文 146 Pages
納期
即納可能 即納可能とは
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.82円
アジア太平洋のてんかん市場の2030年までの予測 - 地域別分析：タイプ別、投与経路別、治療タイプ別、年齢層別、流通チャネル別
出版日: 2024年09月16日
発行: The Insight Partners
ページ情報: 英文 146 Pages
納期: 即納可能 即納可能とは
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

アジア太平洋のてんかん市場は、2022年には22億92万米ドルとなり、2030年までには31億4,344万米ドルに達すると予測され、2022年から2030年までのCAGRは4.6%と推定されます。

団体による啓発プログラムの急増がアジア太平洋のてんかん市場を後押し

てんかんやその症状、早期診断の重要性に対する認識が高まり、医療機関を受診する患者が急増しています。Epilepsy Foundation、Epilepsy Society、American Epilepsy Society、Epilepsy Association of Central Floridaなどの団体は、てんかんという病気について人々を啓蒙する上で重要な役割を果たしています。これらの団体の関与により、診断率が向上し、てんかん治療を必要とする患者層が拡大しています。また、てんかんの症状や治療法に関する認識を広めるため、世界各地の団体により数多くの啓発キャンペーンが実施されています。2023年の「てんかんのパープルデー」に、ハイデラバード（インド）のAster Prime Hospitalsは、Walkers Association of Krishna Kant Parkと共同で啓発活動を行いました。このセッションには、ウォーカーやヨガの実践者を含む合計150人が参加しました。さらに、てんかんを持つオーストラリア人の生活の質を向上させるため、Epilepsy Action Australiaは、啓発、教育、必要なスキルの習得を目的とした様々なツールやサービスを提供しています。このような取り組みや啓発キャンペーンは、てんかんの診断や治療の増加につながり、市場に有益な成長機会をもたらしています。

アジア太平洋のてんかん市場概要

アジア太平洋のてんかん市場は、中国、日本、インド、オーストラリア、韓国、その他アジア太平洋に基づいて分析されます。世界保健機関（WHO）の報告によると、てんかんの有病率は先進国よりも新興諸国の方が高く、それぞれ6.1%と5.0%を占めています。

アジア太平洋のてんかん市場の収益と2030年までの予測（金額）

アジア太平洋のてんかん市場のセグメンテーション

アジア太平洋のてんかん市場は、タイプ、投与経路、治療タイプ、年齢層、流通チャネル、国に分類されます。

タイプ別では、アジア太平洋のてんかん市場は進行性ミオクロニーてんかん、反射性てんかん、全般てんかん、その他に分類されます。2022年の市場シェアは全般てんかんが最大でした。

投与経路では、アジア太平洋のてんかん市場は経口、非経口、その他に分類されます。2022年には経口セグメントが最大の市場シェアを占めました。

治療タイプ別では、アジア太平洋のてんかん市場は第一世代医薬品、第二世代医薬品、第三世代医薬品に分類されます。2022年には、第3世代薬セグメントが最大の市場シェアを占めました。

年齢層に基づくと、アジア太平洋のてんかん市場は大人と子供に二分されます。2022年の市場シェアは、成人セグメントがより大きいです。

流通チャネルでは、アジア太平洋のてんかん市場は病院薬局、小売薬局、その他に分類されます。病院薬局セグメントが2022年に最も大きな市場シェアを占めました。

国別では、アジア太平洋のてんかん市場は中国、日本、インド、オーストラリア、韓国、その他アジア太平洋に区分されます。2022年のアジア太平洋のてんかん市場シェアは中国が独占しました。

Abbott Laboratories、Pfizer Inc、Eisai Co Ltd、UCB SA、LivaNova Plc、Novartis AG、Medtronic Plc、GSK Plc、H. Lundbeck ASは、アジア太平洋のてんかん市場で事業を展開する主要企業です。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

  • 主要洞察
  • 市場の魅力

第3章 調査手法

  • 調査範囲
  • 2次調査
  • 1次調査

第4章 アジア太平洋におけるてんかん治療薬のパイプライン研究

  • てんかん治療アプローチのパイプライン研究
    • 細胞・遺伝子治療アプローチ
    • カプセル化細胞バイオデリバリー（ECB）システム
    • てんかんに対する遺伝子治療の臨床概要
      • てんかんの臨床研究に採用されている遺伝子療法
      • てんかんに対するウイルスベクターのパイプライン研究
      • てんかん非ウイルス性ベクターのパイプライン研究
      • アデノ随伴ウイルス（AAV）を介した神経調節ペプチド-概要
      • 遺伝子治療のための神経栄養因子
      • ヒトてんかん表現型に対するカリウムチャネル
      • 酵素誘導性抗てんかん薬

第5章 アジア太平洋のてんかん市場：主要市場力学

  • 市場促進要因
    • てんかん有病率の上昇
    • てんかん治療薬開発への投資の増加
  • 市場抑制要因
    • 製品の回収
  • 市場機会
    • 団体による啓発プログラムの急増
  • 今後の動向
    • 有望な治療アプローチとしての遺伝子治療
  • 促進要因と抑制要因の影響

第6章 てんかん市場：アジア太平洋の分析

  • アジア太平洋のてんかん市場

第7章 アジア太平洋のてんかん市場分析：タイプ別

  • 進行性ミオクロニーてんかん
  • 反射性てんかん
  • 全般てんかん
  • その他

第8章 アジア太平洋のてんかん市場分析：投与経路別

  • 経口
  • 非経口
  • その他

第9章 アジア太平洋のてんかん市場分析：治療タイプ別

  • 第一世代医薬品
  • 第二世代医薬品
  • 第三世代医薬品

第10章 アジア太平洋のてんかん市場分析：年齢層別

  • 大人
  • 子供

第11章 アジア太平洋のてんかん市場分析：流通チャネル別

  • 病院薬局
  • 小売薬局
  • その他

第12章 アジア太平洋のてんかん市場：国別分析

    • アジア太平洋
      • 中国
      • 日本
      • インド
      • オーストラリア
      • 韓国
      • その他アジア太平洋

第13章 業界情勢

  • てんかん市場の成長戦略
  • 有機的成長戦略
  • 無機的成長戦略

第14章 企業プロファイル

  • Abbott Laboratories
  • Pfizer Inc
  • Eisai Co Ltd
  • UCB SA
  • LivaNova Plc
  • Novartis AG
  • Medtronic Plc
  • GSK Plc
  • H. Lundbeck AS

第15章 付録

図表

List Of Tables

  • Table 1. Asia Pacific Epilepsy Market Segmentation
  • Table 2. Cell Therapy Approach - An Overview
  • Table 3. Gene Therapy Approach - An Overview
  • Table 4. Encapsulated cell bio delivery (ECB) system Cell and Gene Therapy Approach - An Overview
  • Table 5. Preclinically Tested Genetic Therapies for Epilepsy
  • Table 6. Clinical Trials for Epilepsy Gene Therapy: Overview
  • Table 7. Viral Vectors Comparison with respect to Various Parameters
  • Table 8. Subfamilies of Human K+ Channels Involved in Epilepsies
  • Table 9. Enzyme-Inducing Antiepileptic Drugs
  • Table 10. Enzyme-Inducing Antiepileptic Drugs & Drug Targets Types Overview
  • Table 11. China: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 12. China: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
  • Table 13. China: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Treatment Type
  • Table 14. China: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Age Group
  • Table 15. China: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
  • Table 16. Japan: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 17. Japan: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
  • Table 18. Japan: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Treatment Type
  • Table 19. Japan: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Age Group
  • Table 20. Japan: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
  • Table 21. India: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 22. India: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
  • Table 23. India: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Treatment Type
  • Table 24. India: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Age Group
  • Table 25. India: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
  • Table 26. Australia: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 27. Australia: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
  • Table 28. Australia: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Treatment Type
  • Table 29. Australia: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Age Group
  • Table 30. Australia: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
  • Table 31. South Korea: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 32. South Korea: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
  • Table 33. South Korea: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Treatment Type
  • Table 34. South Korea: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Age Group
  • Table 35. South Korea: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
  • Table 36. Rest of Asia Pacific: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 37. Rest of Asia Pacific: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
  • Table 38. Rest of Asia Pacific: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Treatment Type
  • Table 39. Rest of Asia Pacific: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Age Group
  • Table 40. Rest of Asia Pacific: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
  • Table 41. Recent Organic Growth Strategies in Epilepsy Market
  • Table 42. Recent Inorganic Growth Strategies in the Epilepsy Market

List Of Figures

  • Figure 1. Asia Pacific Epilepsy Market Segmentation, by Country
  • Figure 2. Epilepsy Market - Key Market Dynamics
  • Figure 3. Impact Analysis of Drivers and Restraints
  • Figure 4. Epilepsy Market Revenue (US$ Million), 2020-2030
  • Figure 5. Epilepsy Market Share (%) - by Type (2022 and 2030)
  • Figure 6. Progressive Myoclonic Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 7. Reflex Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 8. Generalized Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 9. Other: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 10. Epilepsy Market Share (%) - by Route of Administration (2022 and 2030)
  • Figure 11. Oral: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 12. Parenteral: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 13. Others: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 14. Epilepsy Market Share (%) - by Treatment Type (2022 and 2030)
  • Figure 15. First Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 16. Second Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 17. Third Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 18. Epilepsy Market Share (%) - by Age Group (2022 and 2030)
  • Figure 19. Adult: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 20. Children: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 21. Epilepsy Market Share (%) - by Distribution Channel (2022 and 2030)
  • Figure 22. Hospital Pharmacies: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 23. Retail Pharmacies: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 24. Others: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 25. Asia Pacific: Epilepsy Market, by Key Country - Revenue (2022) (US$ Million)
  • Figure 26. Asia Pacific: Epilepsy Market Breakdown, by Key Countries, 2022 and 2030 (%)
  • Figure 27. China: Epilepsy Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 28. Japan: Epilepsy Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 29. India: Epilepsy Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 30. Australia: Epilepsy Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 31. South Korea: Epilepsy Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 32. Rest of Asia Pacific: Epilepsy Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 33. Growth Strategies in Epilepsy Market
目次
Product Code: BMIRE00030724

The Asia Pacific epilepsy market was valued at US$ 2,200.92 million in 2022 and is expected to reach US$ 3,143.44 million by 2030; it is estimated to register a CAGR of 4.6% from 2022 to 2030.

Surge in Awareness Program Conducted by Organizations Boosts Asia Pacific Epilepsy Market

Growing awareness about epilepsy, its symptoms, and the importance of early diagnosis has led to a surge in patients seeking medical attention. Organizations such as the Epilepsy Foundation, Epilepsy Society, the American Epilepsy Society, and the Epilepsy Association of Central Florida play a crucial role in educating people about this disease. The involvement of these organizations has resulted in increased rates of diagnosis and a broader patient population requiring epilepsy treatment. Numerous awareness campaigns are conducted by organizations worldwide to spread awareness regarding the condition and available treatment. In 2023, on the Purple Day of Epilepsy, Aster Prime Hospitals in Hyderabad (India), in collaboration with the Walkers Association of Krishna Kant Park, held an awareness activity. One hundred fifty participants in total, including walkers and yoga practitioners, attended this session. Additionally, in order to improve the quality of life for Australians living with epilepsy, Epilepsy Action Australia offers a variety of tools and services aimed at raising awareness, educating, and equipping individuals with the necessary skills. Thus, such initiatives and awareness campaigns result in an increase in epilepsy diagnoses and treatments, offering lucrative growth opportunities to the market.

Asia Pacific Epilepsy Market Overview

The Asia Pacific epilepsy market is analyzed based on China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. According to the World Health Organization (WHO) report, epilepsy is more common in developing countries than in developed countries, accounting for a prevalence of 6.1% and 5.0%, respectively.

Asia Pacific Epilepsy Market Revenue and Forecast to 2030 (US$ Million)

Asia Pacific Epilepsy Market Segmentation

The Asia Pacific epilepsy market is categorized into type, route of administration, treatment type, age group, distribution channel, and country.

Based on type, the Asia Pacific epilepsy market is categorized into progressive myoclonic epilepsy, reflex epilepsy, generalized epilepsy, and other. The generalized epilepsy segment held the largest market share in 2022.

In terms of route of administration, the Asia Pacific epilepsy market is categorized into oral, parenteral, and others. The oral segment held the largest market share in 2022.

By treatment type, the Asia Pacific epilepsy market is segmented into first generation drugs, second generation drugs, and third generation drugs. The third generation drugs segment held the largest market share in 2022.

Based on age group, the Asia Pacific epilepsy market is bifurcated into adult and children. The adult segment held a larger market share in 2022.

In terms of distribution channel, the Asia Pacific epilepsy market is categorized into hospital pharmacies, retail pharmacies, and others. The hospital pharmacies segment held the largest market share in 2022.

By country, the Asia Pacific epilepsy market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. China dominated the Asia Pacific epilepsy market share in 2022.

Abbott Laboratories, Pfizer Inc, Eisai Co Ltd, UCB SA, LivaNova Plc, Novartis AG, Medtronic Plc, GSK Plc, and H. Lundbeck AS are some of the leading companies operating in the Asia Pacific epilepsy market.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights
  • 2.2 Market Attractiveness

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. Asia Pacific Pipeline Studies for Epilepsy Therapy Approaches

  • 4.1 Pipeline Studies for Epilepsy Therapy Approaches
    • 4.1.1 Cell and Gene Therapy Approaches
    • 4.1.2 Encapsulated cell bio delivery (ECB) system
    • 4.1.3 Gene Therapy for Epilepsy Clinical Overview
      • 4.1.3.1 Genetic Therapies Adopted for Clinic Research of Epilepsy
        • 4.1.3.1.1 Gene Supplementation - Overview
        • 4.1.3.1.2 Gene Modulation - Overview
        • 4.1.3.1.3 Antisense Oligonucleotides and RNA Interference - Overview
        • 4.1.3.1.4 Neuropeptides - Overview
        • 4.1.3.1.5 Engineered Channels - Overview
        • 4.1.3.1.6 Endogenous Channels - Overview
      • 4.1.3.2 Pipeline Studies of Viral Vectors for Epilepsy
      • 4.1.3.3 Pipeline Studies of Non-Viral Vectors for Epilepsy
        • 4.1.3.3.1 Polymer-based Non-Viral Vectors for Epilepsy
        • 4.1.3.3.2 Lipid-based Non-Viral Vectors for Epilepsy
      • 4.1.3.4 Adeno-Associated Virus (AAV)-Mediated Neuromodulatory Peptides - Overview
      • 4.1.3.5 Neurotrophic Factors for Gene Therapy Approaches
      • 4.1.3.6 Potassium Channels For Human Epileptic Phenotypes
      • 4.1.3.7 Enzyme Inducing Antiepileptic Drugs

5. Asia Pacific Epilepsy Market - Key Market Dynamics

  • 5.1 Market Drivers
    • 5.1.1 Rising Prevalence of Epilepsy
    • 5.1.2 Increasing Investments in Development of Epilepsy Therapies
  • 5.2 Market Restraints
    • 5.2.1 Recall of Products
  • 5.3 Market Opportunities
    • 5.3.1 Surge in Awareness Programs Conducted by Organizations
  • 5.4 Future Trends
    • 5.4.1 Gene Therapy as Promising Treatment Approach
  • 5.5 Impact of Drivers and Restraints:

6. Epilepsy Market - Asia Pacific Analysis

  • 6.1 Asia Pacific: Epilepsy Market

7. Asia Pacific Epilepsy Market Analysis - by Type

  • 7.1 Overview
  • 7.2 Progressive Myoclonic Epilepsy
    • 7.2.1 Overview
    • 7.2.2 Progressive Myoclonic Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.3 Reflex Epilepsy
    • 7.3.1 Overview
    • 7.3.2 Reflex Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.4 Generalized Epilepsy
    • 7.4.1 Overview
    • 7.4.2 Generalized Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.5 Other
    • 7.5.1 Overview
    • 7.5.2 Other: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

8. Asia Pacific Epilepsy Market Analysis - by Route of Administration

  • 8.1 Overview
  • 8.2 Oral
    • 8.2.1 Overview
    • 8.2.2 Oral: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.3 Parenteral
    • 8.3.1 Overview
    • 8.3.2 Parenteral: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.4 Others
    • 8.4.1 Overview
    • 8.4.2 Others: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

9. Asia Pacific Epilepsy Market Analysis - by Treatment Type

  • 9.1 Overview
  • 9.2 First Generation Drugs
    • 9.2.1 Overview
    • 9.2.2 First Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • 9.3 Second Generation Drugs
    • 9.3.1 Overview
    • 9.3.2 Second Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • 9.4 Third Generation Drugs
    • 9.4.1 Overview
    • 9.4.2 Third Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

10. Asia Pacific Epilepsy Market Analysis - by Age Group

  • 10.1 Overview
  • 10.2 Adult
    • 10.2.1 Overview
    • 10.2.2 Adult: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • 10.3 Children
    • 10.3.1 Overview
    • 10.3.2 Children: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

11. Asia Pacific Epilepsy Market Analysis - by Distribution Channel

  • 11.1 Overview
  • 11.2 Hospital Pharmacies
    • 11.2.1 Overview
    • 11.2.2 Hospital Pharmacies: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • 11.3 Retail Pharmacies
    • 11.3.1 Overview
    • 11.3.2 Retail Pharmacies: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • 11.4 Others
    • 11.4.1 Overview
    • 11.4.2 Others: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

12. Asia Pacific Epilepsy Market - Country Analysis

  • 12.1 Asia Pacific Epilepsy Market Overview
    • 12.1.1 Asia Pacific: Epilepsy Market Breakdown, by Key Country, 2022 and 2030 (%)
      • 12.1.1.1 China: Epilepsy Market Overview
      • 12.1.1.2 China: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
        • 12.1.1.2.1 China: Epilepsy Market Breakdown, by Type
        • 12.1.1.2.2 China: Epilepsy Market Breakdown, by Route of Administration
        • 12.1.1.2.3 China: Epilepsy Market Breakdown, by Treatment Type
        • 12.1.1.2.4 China: Epilepsy Market Breakdown, by Age Group
        • 12.1.1.2.5 China: Epilepsy Market Breakdown, by Distribution Channel
      • 12.1.1.3 Japan: Epilepsy Market Overview
      • 12.1.1.4 Japan: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
        • 12.1.1.4.1 Japan: Epilepsy Market Breakdown, by Type
        • 12.1.1.4.2 Japan: Epilepsy Market Breakdown, by Route of Administration
        • 12.1.1.4.3 Japan: Epilepsy Market Breakdown, by Treatment Type
        • 12.1.1.4.4 Japan: Epilepsy Market Breakdown, by Age Group
        • 12.1.1.4.5 Japan: Epilepsy Market Breakdown, by Distribution Channel
      • 12.1.1.5 India: Epilepsy Market Overview
      • 12.1.1.6 India: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
        • 12.1.1.6.1 India: Epilepsy Market Breakdown, by Type
        • 12.1.1.6.2 India: Epilepsy Market Breakdown, by Route of Administration
        • 12.1.1.6.3 India: Epilepsy Market Breakdown, by Treatment Type
        • 12.1.1.6.4 India: Epilepsy Market Breakdown, by Age Group
        • 12.1.1.6.5 India: Epilepsy Market Breakdown, by Distribution Channel
      • 12.1.1.7 Australia: Epilepsy Market Overview
      • 12.1.1.8 Australia: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
        • 12.1.1.8.1 Australia: Epilepsy Market Breakdown, by Type
        • 12.1.1.8.2 Australia: Epilepsy Market Breakdown, by Route of Administration
        • 12.1.1.8.3 Australia: Epilepsy Market Breakdown, by Treatment Type
        • 12.1.1.8.4 Australia: Epilepsy Market Breakdown, by Age Group
        • 12.1.1.8.5 Australia: Epilepsy Market Breakdown, by Distribution Channel
      • 12.1.1.9 South Korea: Epilepsy Market Overview
      • 12.1.1.10 South Korea: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
        • 12.1.1.10.1 South Korea: Epilepsy Market Breakdown, by Type
        • 12.1.1.10.2 South Korea: Epilepsy Market Breakdown, by Route of Administration
        • 12.1.1.10.3 South Korea: Epilepsy Market Breakdown, by Treatment Type
        • 12.1.1.10.4 South Korea: Epilepsy Market Breakdown, by Age Group
        • 12.1.1.10.5 South Korea: Epilepsy Market Breakdown, by Distribution Channel
      • 12.1.1.11 Rest of Asia Pacific: Epilepsy Market Overview
      • 12.1.1.12 Rest of Asia Pacific: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
        • 12.1.1.12.1 Rest of Asia Pacific: Epilepsy Market Breakdown, by Type
        • 12.1.1.12.2 Rest of Asia Pacific: Epilepsy Market Breakdown, by Route of Administration
        • 12.1.1.12.3 Rest of Asia Pacific: Epilepsy Market Breakdown, by Treatment Type
        • 12.1.1.12.4 Rest of Asia Pacific: Epilepsy Market Breakdown, by Age Group
        • 12.1.1.12.5 Rest of Asia Pacific: Epilepsy Market Breakdown, by Distribution Channel

13. Industry Landscape

  • 13.1 Overview
  • 13.2 Growth Strategies in Epilepsy Market
  • 13.3 Organic Growth Strategies
    • 13.3.1 Overview
  • 13.4 Inorganic Growth Strategies
    • 13.4.1 Overview

14. Company Profiles

  • 14.1 Abbott Laboratories
    • 14.1.1 Key Facts
    • 14.1.2 Business Description
    • 14.1.3 Products and Services
    • 14.1.4 Financial Overview
    • 14.1.5 SWOT Analysis
    • 14.1.6 Key Developments
  • 14.2 Pfizer Inc
    • 14.2.1 Key Facts
    • 14.2.2 Business Description
    • 14.2.3 Products and Services
    • 14.2.4 Financial Overview
    • 14.2.5 SWOT Analysis
    • 14.2.6 Key Developments
  • 14.3 Eisai Co Ltd
    • 14.3.1 Key Facts
    • 14.3.2 Business Description
    • 14.3.3 Products and Services
    • 14.3.4 Financial Overview
    • 14.3.5 SWOT Analysis
    • 14.3.6 Key Developments
  • 14.4 UCB SA
    • 14.4.1 Key Facts
    • 14.4.2 Business Description
    • 14.4.3 Products and Services
    • 14.4.4 Financial Overview
    • 14.4.5 SWOT Analysis
    • 14.4.6 Key Developments
  • 14.5 LivaNova Plc
    • 14.5.1 Key Facts
    • 14.5.2 Business Description
    • 14.5.3 Products and Services
    • 14.5.4 Financial Overview
    • 14.5.5 SWOT Analysis
    • 14.5.6 Key Developments
  • 14.6 Novartis AG
    • 14.6.1 Key Facts
    • 14.6.2 Business Description
    • 14.6.3 Products and Services
    • 14.6.4 Financial Overview
    • 14.6.5 SWOT Analysis
    • 14.6.6 Key Developments
  • 14.7 Medtronic Plc
    • 14.7.1 Key Facts
    • 14.7.2 Business Description
    • 14.7.3 Products and Services
    • 14.7.4 Financial Overview
    • 14.7.5 SWOT Analysis
    • 14.7.6 Key Developments
  • 14.8 GSK Plc
    • 14.8.1 Key Facts
    • 14.8.2 Business Description
    • 14.8.3 Products and Services
    • 14.8.4 Financial Overview
    • 14.8.5 SWOT Analysis
    • 14.8.6 Key Developments
  • 14.9 H. Lundbeck AS
    • 14.9.1 Key Facts
    • 14.9.2 Business Description
    • 14.9.3 Products and Services
    • 14.9.4 Financial Overview
    • 14.9.5 SWOT Analysis
    • 14.9.6 Key Developments

15. Appendix

  • 15.1 About The Insight Partners